A side note to medications and spinal injury -
Acorda (this has been reported here) is now in Phase Three of the testing of Fampridine-SR for MS. This trial study is short term -21 weeks. I tried to become a participant, but unfortunately I did not meet all the criteria. A participant was to walk 25 ft. in 8 seconds - they were not accepting anyone who could walk faster, which I could. I am disappointed not to be included in the study. But, the good news is that after 21 weeks the medication will probably be on the market as a prescribed medicine for MS.
Because the medicine has already been approved for spinal cord injuries, it will pass through the FDA with less protocal. So, six months (or so) from now we may have a medication to help our walking. Anyone interested in finding out more about Fampridine-SR should check out the Acorda website.